Find out here

WELCOME TO

Use your iPad to present

your brand news &

co l lec t cus tomer data !

D E M O P R E S E N TAT I O N

Why MReply is your best brand partner in digital communication?

Animation

Loop

Animation

Triggering

Navigation in

Presentation

Types of

Answers

What makes MReply unique for consumer?

Additional benefits for your business

Your story in pictures with captivating animations and infinite play before and without user input or any interaction

1A) Animation Loop – Products Rotation

slider 900x100

Display and rotate any creative visuals you like: square ~ slider ~ full-branding ~ pop-up ~ interstitial and more…

1B) Animation Loop - Display Ad Formats

square 300x300

2) Animation TriggeringLet your consumers choose from different products andexpose them to captivating visual content

Use inner connections between slides to get to specific slide

3) Navigation in Slides

Scale option4A) Options – Single Select

Select option by clicking on images

DRESSES

TOPS JEANS TROUSERS

Scale option4B) Feedback

Select satisfaction level

DRESSESHow satisfied are you with the product?

We will send special prices voucher

SEE YOU ON SEPTEMBER 1st

By clicking Submit, I accept privacy statement

Name:

Surname:

Phone:

Email:

4C) FormsFill out forms with intelligent keyboard or by voice

4C) Type of answers

How much do

you like Acidko

yoghurt? (Rank

1-10 )

Describe the taste

with your words

❶

SELECT

❷

INPUT A

❸

INPUT B

4C) FlowFlow of answers can be easilydesigned by your needs

How much do

you like Acidko

yoghurt? (Rank

1-10 )

Describe the taste

with your words

❶

SELECT

❸

INPUT A

❷

INPUT B

Try it out, tapping on both of the

bottles

Team management

Add your team members and select user rights (Agent,

Supervisor, …)

Realtime overview of your team performance

you

supervisor

agent

Performance management

Manage your KPIs, compare your team members performance easily

Agent 2

Agent 1

Database + Export

Direct access to all Q&As for every data input entry Ready for your CRM import Simple versioning system

Customer connectivity

Further analysis and connectivity on demand

SMS instant feedback

E-mail messaging

SMS

LET’S TALK

ABOUT YOUR

BUSINESS

NEEDS

NOW

LET’S TALK ABOUT YOUR BUSINESS NEEDS

SEND

Please, send me examples of latest presentations

THANK

YOU!We will

help you to promote

your brand too!

ACIP RecommendationsSupport

ACIP recommends that a MenB vaccine series may be administered to adolescents and

young adults aged 16 through 23 years to provide short-term protection against most

strains of MenB disease. The preferred age for MenB vaccination is 16 through 18

years. The decision to vaccinate should be made at the individual level by healthcare

providers.

ACIP recommends certain persons aged ≥10 years who are at increased risk for

meningococcal disease should receive MenB vaccine. These persons include:

• Persons with persistent complement component deficiencies

• Persons with anatomic or functional asplenia, including sickle cell disease

• Microbiologists routinely exposed to isolates of Neisseria meningitidis

• Persons identified as at increased risk because of a MenB disease outbreak

Individuals at increased risk for MenB should be vaccinated, according to ACIP

How Trumenba worksSupport

TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H

binding protein (fHBP)—which is found on more than 97% of all MenB strains.

This method generates antibodies capable of destroying a range of MenB strains.

TRUMENBA targets a protein found in >97% of MenB strains

The fHBP Discovery

Pfizer used a combined biochemical and immunological screening approach to identify

surface-expressed proteins on MenB strains that were capable of producing antibodies

that could kill diverse meningococcal strains. During this process, fHBP elicited robust

bactericidal responses

Cross-CoverageSupport

TRUMENBA demonstrated cross-

coverage by targeting MenB

strains expressing both

subfamilies, A and B, of fHBP

TRUMENBA is the only MenB

vaccine that was tested against 4

prevalent strains in the US and

Europe

*In a randomized, placebo-controlled, single-blinded, multicenter trial conducted in Europe, 1713 adolescents 11 through 18 years of age were assigned randomly into 5 groups to receive 2 or 3 doses of TRUMENBA: Group 1 (0, 1, and 6 months); Group 2 (0, 2, and 6 months); Group 3 (0 and 6 months); Group 4 (0 and 2 months); Group 5 (0 and 4 months).1,2

†To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline hSBA titer ≥1:4, an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.